NCT03337620View on ClinicalTrials.gov

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

November 15, 2023

Study Completion Date

December 29, 2023

Conditions
Headache, Migraine
Interventions
DEVICE

Tx360

Tx360 used to deliver active and placebo drug interventions to SPG.

Trial Locations (11)

10007

Hudson Medical, New York

11776

North Suffolk Neurology, PC, Port Jefferson Station

15236

Preferred Primary Care Physicians, Pittsburgh

28310

Womack Army Medical Senter, Fort Bragg

30905

Eisenhower Army Medical Center, Fort Gordon

65810

Clinvest Research, LLC, Springfield

70043

Crescent City Headache and Neurology Centre, Chalmette

75035

Lone Star Neurology, Frisco

06519

Yale University, New Haven

06905

New England Institute for Clinical Research, Stamford

02472

MedVadis Research, Watertown

Sponsors

Collaborators (1)

Clinvest Research, LLC
All Listed Sponsors
collaborator

TAMM Net, Inc.

UNKNOWN

collaborator

Clinvest Research, LLC

INDUSTRY

collaborator

Ki Health Partners. LLC

INDUSTRY

lead

Tian Medical Inc.

INDUSTRY

NCT03337620 - Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine | Biotech Hunter | Biotech Hunter